Condition: Metastatic Renal Cell Carcinoma ( mRCC) · OligoProgressive Metastatic Disease · Sponsor: University of Texas Southwestern Medical Center
To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
This description comes directly from the study's public registry record.
SARAH NEUFELD, MANAGER OF CLINICAL RESEARCH, MS, MBA · 214 648 1836 · Sarah.Hardee@UTSouthwestern.edu
RAQUIBUL HANNAN, MD, PhD. · 214 645 7696 · Raquibul.Hannan@UTSouthwestern.edu
Always discuss trial participation with your own doctor first.
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06601296